CORT
Corcept Therapeutics Inc
$91.88
-1.37 (-1.47%)
At close · Jul 10
Market Cap
$9.86B
Shares
107,351,594
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$761.41M
+12.8%
FY2025
Net Income
$99.65M
-29.4%
FY2025
Gross Margin
98.3%
-0.1pp
FY2025
Operating Margin
5.88%
-14.4pp
FY2025
Diluted EPS
$0.82
-33.3%
FY2025
Operating Cash Flow
$142M
-28.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $950M – $1.05B | $769.1M | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M | $353.87M | $306.49M | $251.25M | $159.2M | $81.32M | — | — | — | — | $1.01M | — | $29K | — | — | — | — | — | — | — | — | |
| — | $13.46M | $12.98M | $10.88M | $6.48M | $5.39M | $5.28M | $5.58M | $5.5M | $5.22M | $3.55M | $2.06M | $1.36M | $882K | $143K | $91K | — | — | — | — | — | — | — | — | — | — | — | |
| — | $755.64M | $748.43M | $664.16M | $475.89M | $396.47M | $360.7M | $348.29M | $300.98M | $246.03M | $155.65M | $79.26M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 98.3% | 98.39% | 98.66% | 98.66% | 98.56% | 98.42% | 98.2% | 97.92% | 97.77% | 97.47% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $260.44M | $254.91M | $246.89M | $184.35M | $130.99M | $113.86M | $114.76M | $89.02M | $75.25M | $40.38M | $23.84M | $15.42M | $18.37M | $20.47M | $14.07M | $21M | $18.95M | $14.4M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $60.58M | $8.49M | $5.88M | — | — | — | — | — | — | — | — | |
| — | $503.42M | $448.73M | $280.32M | $184.26M | $152.85M | $122.36M | $105.33M | $100.36M | $81.29M | $62.42M | $45.24M | $36.95M | $34.92M | $31.24M | $25.41M | $11.33M | $8.49M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $465K | $477K | $409K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $1.15M | $795K | $1.04M | $1.26M | $1.07M | $525K | $703K | $236K | $106K | $87K | $155K | $141K | $74K | $27K | $3000 | $6000 | $10K | — | — | — | — | — | — | — | — | |
| — | $52.5M | — | — | — | — | — | — | — | — | — | — | — | $54.17M | $51.85M | $39.58M | $32.33M | $27.44M | $20.28M | — | — | — | — | — | — | — | — | |
| — | $777.32M | $716.61M | $538.09M | $375.09M | $289.22M | $241.5M | $225.67M | $194.88M | $161.75M | $106.35M | $71.14M | $53.73M | $54.17M | $51.85M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$8.22M | $44.8M | $136.95M | $107.28M | $112.63M | $124.48M | $128.2M | $111.61M | $89.5M | $52.86M | $10.18M | -$3.44M | -$27.62M | -$41.5M | -$36.27M | -$32.33M | -$27.44M | -$20.25M | — | — | — | — | — | — | — | — | |
| — | — | 5.88% | 20.29% | 22.24% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.2% | 12.52% | — | — | — | — | -3188.56% | — | -69827.59% | — | — | — | — | — | — | — | — | |
| — | — | $45.95M | $137.75M | $108.32M | $113.89M | $125.55M | $128.73M | $112.31M | $89.73M | $52.96M | $10.27M | -$3.29M | -$27.48M | -$41.42M | -$36.25M | -$32.33M | -$27.43M | -$20.24M | — | — | — | — | — | — | — | — | |
| — | $20.35M | $21.67M | $24.54M | $17.28M | $3.56M | $529K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $12.13M | $66.46M | $161.49M | $124.56M | $116.19M | $125.01M | $131.6M | $116.68M | $92.15M | $52.81M | $8.14M | -$6.41M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$35.21M | -$33.19M | $20.28M | $18.42M | $14.77M | $12.49M | $25.59M | $22.5M | $16.74M | -$76.32M | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $47.34M | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M | $106.01M | $94.18M | $75.41M | $129.12M | $8.14M | -$6.41M | -$31.38M | -$46.01M | -$38.05M | -$32.35M | -$25.97M | -$20.17M | -$20.06M | -$11.57M | -$24.87M | -$20.09M | -$15.54M | -$9.81M | -$18.5M | -$7.45M | |
| — | — | 13.09% | 20.92% | 22% | 25.24% | 30.74% | 29.96% | 30.73% | 30.01% | 81.11% | 10.01% | — | — | — | — | -3190.73% | — | -69537.93% | — | — | — | — | — | — | — | — | |
| — | $46.68M | $98.17M | $139.73M | $105.5M | $101.29M | $112.51M | $106.01M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $47.57M | $102.13M | $140.38M | $107.62M | $100.78M | $111.87M | $106.17M | $94.51M | $75.42M | $129.05M | $8.14M | -$6.41M | -$31.38M | -$46.01M | -$38.05M | -$32.35M | -$25.97M | -$20.17M | -$20.07M | -$11.57M | -$24.77M | -$20.14M | -$15.6M | -$9.81M | — | — | |
| USD/shares | — | — | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 | $0.82 | $0.65 | $1.14 | $0.07 | -$0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | — | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | -$0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | 103.86M | 103.23M | 103.56M | 106.79M | 115.65M | 115.41M | 114.35M | 115.34M | 113.53M | 110.57M | 106.88M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | — | — | — | — | — | — | — | — | — |
| shares | — | — | 119.99M | 113.48M | 111.74M | 115.97M | 125.96M | 124.19M | 122.57M | 126.69M | 124.52M | 116.14M | 106.88M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $253.16M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
262.51×
Biotechnology median 7.52×
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1088856
CUSIP
218352102
13F (30d)
18 filings
14 filers
Visit website
Investor relations